Erick Lu

Erick Lu

Auto-generated profile, based on publicly available information

Erick Lu

Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94143, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Immunity
Verified
Journal Article
Closed access
LRLauren B. Rodda
Lauren B. Rodda
ELErick Lu
Erick Lu
MBMariko L. Bennett
Mariko L. Bennett
CSCaroline L. Sokol
Caroline L. Sokol
XWXiaoming Wang
Xiaoming Wang
JCJason G. Cyster
Jason G. Cyster

1 October 2021 in Cell Reports
Verified
Journal Article
Open access
MBMikhail Binnewies
Mikhail Binnewies
JPJoshua L. Pollack
Joshua L. Pollack
JRJoshua Rudolph
Joshua Rudolph
SDSubhadra Dash
Subhadra Dash
MAMarwan Abushawish
Marwan Abushawish
VSVenkataraman Sriram
Venkataraman Sriram
Converting checkpoint inhibitor (CPI)-resistant individuals to being responsive requires identifying suppressive mechanisms. We identify TREM2+ tumor-associated macrophages (TAMs) as being correlated with exhausted CD8+ tumor-infiltrating lymphocytes (TILs) in mouse syngeneic tumor models and human solid tumors of multiple histological types. Fc domain-enhanced anti-TREM2 monoclonal antibody (mAb) therapy promotes anti-tumor immunity by elimination and modulation of TAM populations, which leads to enhanced CD8+ TIL infiltration and effector function. TREM2+ TAMs are most enriched in individuals with ovarian cancer, where TREM2 expression corresponds to disease grade accompanied by worse recurrence-free survival. In an aggressive orthotopic ovarian cancer model, anti-TREM2 mAb therapy drives potent anti-tumor immunity. These results highlight TREM2 as a highly attractive target for immunotherapy modulation in individuals who are refractory to CPI therapy and likely have a TAM-rich tumor microenvironment.

5 May 2016 in Nature
Verified
Journal Article
Open access
PDF file
JLJianhua Li
Jianhua Li
ELErick Lu
Erick Lu
TYTangsheng Yi
Tangsheng Yi
JCJason G. Cyster
Jason G. Cyster
The differentiation of T follicular helper cells requires the G-protein-coupled receptor Ebi2 as well as the interaction with CD25-producing dendritic cells that quench T-cell-derived interleukin-2. The T-cell subset known as T follicular helper (Tfh) cells are crucial for mounting antibody responses, but the cues that guide their positioning and development are incompletely understood. Here Jianhua Li et al. demonstrate that the differentiation of Tfh cells requires the G-protein-coupled receptor EBI2 (also called GPR183), as well as the interaction with CD25-producing dendritic cells that quench T-cell-derived interleukin-2. T follicular helper (Tfh) cells are a subset of T cells carrying the CD4 antigen; they are important in supporting plasma cell and germinal centre responses1,2. The initial induction of Tfh cell properties occurs within the first few days after activation by antigen recognition on dendritic cells, although how dendritic cells promote this cell-fate decision is not fully understood1,2. Moreover, although Tfh cells are uniquely defined by expression of the follicle-homing receptor CXCR5 (refs 1, 2), the guidance receptor promoting the earlier localization of activated T cells at the interface of the B-cell follicle and T zone has been unclear3,4,5. Here we show that the G-protein-coupled receptor EBI2 (GPR183) and its ligand 7α,25-dihydroxycholesterol mediate positioning of activated CD4 T cells at the interface of the follicle and T zone. In this location they interact with activated dendritic cells and are exposed to Tfh-cell-promoting inducible co-stimulator (ICOS) ligand. Interleukin-2 (IL-2) is a cytokine that has multiple influences on T-cell fate, including negative regulation of Tfh cell differentiation6,7,8,9,10. We demonstrate that activated dendritic cells in the outer T zone further augment Tfh cell differentiation by producing membrane and soluble forms of CD25, the IL-2 receptor α-chain, and quenching T-cell-derived IL-2. Mice lacking EBI2 in T cells or CD25 in dendritic cells have reduced Tfh cells and mount defective T-cell-dependent plasma cell and germinal centre responses. These findings demonstrate that distinct niches within the lymphoid organ T zone support distinct cell fate decisions, and they establish a function for dendritic-cell-derived CD25 in controlling IL-2 availability and T-cell differentiation.

21 April 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
ELErick Lu
Erick Lu
EDEric V. Dang
Eric V. Dang
JMJeffrey G. McDonald
Jeffrey G. McDonald
JCJason G. Cyster
Jason G. Cyster
Correct positioning of dendritic cells (DCs) is critical for efficient pathogen encounter and antigen presentation. Epstein-Barr virus–induced gene 2 (EBI2) has been identified as a chemoattractant receptor required for naïve CD4+DCIR2+ DC positioning in response to 7α,25-hydroxycholesterol (7α,25-HC). We now provide evidence that a second EBI2 ligand, 7α,27-HC, is involved in splenic DCIR2+ DC positioning and homeostasis. Cyp27a1, the enzyme uniquely required for 7α,27-HC synthesis, is expressed by stromal cells in the region of naïve DC localization. After activation, DCIR2+ DCs move into the T cell zone. We find that EBI2 is rapidly up-regulated in DCIR2+ DCs under certain activation conditions, and positioning at the B-T zone interface depends on EBI2. Under conditions of type I interferon induction, EBI2 ligand levels are elevated, causing activated DCIR2+ DCs to disperse throughout the T zone. Last, we provide evidence that oxysterol metabolism by Batf3-dependent DCs is important for EBI2-dependent positioning of activated DCIR2+ DCs. This work indicates that 7α,27-HC functions as a guidance cue in vivo and reveals a multitiered role for EBI2 in DC positioning. Deficiency in this organizing system results in defective CD4+ T cell responses.

6 March 2019 in Nature
Verified
Journal Article
Closed access
PDF file
ELErick Lu
Erick Lu
FWFinn D. Wolfreys
Finn D. Wolfreys
JMJagan R. Muppidi
Jagan R. Muppidi
YXYing Xu
Ying Xu
JCJason G. Cyster
Jason G. Cyster

11 February 2022 in Science
Verified
Journal Article
Closed access
DLDan Liu
Dan Liu
LDLihui Duan
Lihui Duan
LRLauren B. Rodda
Lauren B. Rodda
ELErick Lu
Erick Lu
YXYing Xu
Ying Xu
JCJason G. Cyster
Jason G. Cyster
Dendritic cells (DCs) are crucial for initiating adaptive immune responses. However, the factors that control DC positioning and homeostasis are incompletely understood. We found that type-2 conventional DCs (cDC2s) in the spleen depend on Gα 13 and adhesion G protein–coupled receptor family member-E5 (Adgre5, or CD97) for positioning in blood-exposed locations. CD97 function required its autoproteolytic cleavage. CD55 is a CD97 ligand, and cDC2 interaction with CD55-expressing red blood cells (RBCs) under shear stress conditions caused extraction of the regulatory CD97 N-terminal fragment. Deficiency in CD55-CD97 signaling led to loss of splenic cDC2s into the circulation and defective lymphocyte responses to blood-borne antigens. Thus, CD97 mechanosensing of RBCs establishes a migration and gene expression program that optimizes the antigen capture and presentation functions of splenic cDC2s.